جميع الدراسات
التوظيفالمرحلة 3تدخلي

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis

This research study is testing a new medicine called AZ-3102 for rare genetic conditions that affect children and young people. These conditions are Niemann-Pick Type C disease, GM1 gangliosidosis, and GM2 gangliosidosis. The study wants to find out if AZ-3102 is safe to use and if it can help improve the health of those with these conditions. For 18 months, some participants will receive the new medicine, while others will receive a dummy pill (placebo). This helps us understand if any changes are due to the medicine itself. Doctors and participants won't know who is getting which treatment. Researchers will carefully monitor everyone involved to understand the medicine's effects.

نظرة سريعة

الحالة
التوظيف
المرحلة
المرحلة 3
الراعي
Azafaros B.V.
الهدف من التسجيل
147
ابدأ
30 Jun 2025
التاريخ المتوقع للانتهاء
14 Jun 2028

ما هو موضوع هذه الدراسة؟

This study is a research project looking into a new medicine called AZ-3102. It's designed for people, mainly children and young adults, who have one of three rare genetic conditions: Niemann-Pick Type C disease, GM1 gangliosidosis, or GM2 gangliosidosis. These conditions can cause problems with how the body processes certain fats and sugars, leading to various health issues. The main goal is to see if AZ-3102 can safely help improve the health of individuals living with these conditions.

This kind of study involves different groups of people. Some will receive the new medicine, AZ-3102, while others will receive a 'placebo', which looks exactly like the medicine but contains no active ingredients. This is a common way to test new treatments, as it helps researchers figure out if any improvements are genuinely due to the medicine being tested, rather than other factors. Neither the participants, their families, nor their doctors will know who is getting the medicine and who is getting the placebo until the study is over.

The study will last for 18 months, and participants will be closely monitored by a team of medical professionals. They will gather information about the health of everyone involved to see if AZ-3102 makes a difference. Because these conditions have specific features, the study is set up so that information is collected carefully for each condition, even though they are all part of the same overall research programme.

النقاط الرئيسية

  • This study is testing a new medicine (AZ-3102) for rare genetic conditions.
  • It's for children and young people aged 4 and over with specific diagnoses.
  • The study lasts 18 months and involves regular clinic visits.
  • سيحصل المشاركون إما على الدواء الجديد أو على حبة وهمية (بلاسيبو).
  • Neither you nor your doctor will know which treatment you are getting during the study.
  • Your safety and well-being will be closely monitored throughout.

من قد يكون مؤهلاً؟

This study is looking for children and young people who have been diagnosed with certain forms of Niemann-Pick Type C disease, GM1 Gangliosidosis, or GM2 Gangliosidosis.

To be considered, you must be at least 4 years old and have a diagnosis of one of these conditions, specifically the 'late-infantile' or 'juvenile' type. There are also other specific health requirements for each condition that your doctor would need to check.

Generally, those who don't meet these age or diagnosis criteria, or have other certain health issues that might affect the study results, would not be able to take part. Your doctor will have more detailed information about who can and cannot join based on your specific health situation.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. Are you or your child diagnosed with Niemann-Pick Type C, GM1 Gangliosidosis, or GM2 Gangliosidosis?
  2. Is the diagnosis specifically the 'late-infantile' or 'juvenile' form?
  3. Is the person wanting to take part aged 4 years or older?
  4. Are you able to attend regular clinic visits for 18 months?
  5. Are you willing to potentially receive either the study medicine or a placebo?
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

If you decide to take part in this study, you would be involved for a total of 18 months. During this time, you would regularly take the study medication, either AZ-3102 or the placebo, by mouth as instructed by the study doctor. You would have a schedule of visits to the study clinic where the medical team will carry out various checks and assessments.

These assessments might include physical examinations, blood tests, and tests to measure how your condition is affecting you. The exact number and type of visits and tests will depend on which specific condition you have, but they are all designed to keep you safe and to see if the medicine is working. The study team will explain the full schedule of visits and what each involves before you make a decision.

المخاطر والفوائد المحتملة

Taking part in any medical study has both potential benefits and risks. A potential benefit of this study is that AZ-3102 might help improve your health condition, or it could help researchers learn more about these rare diseases and potential future treatments, which could benefit others. However, there's also a chance the medicine might not help, or you might experience side effects. It's important to remember that you can choose to leave the study at any time, for any reason, without it affecting your medical care.

المواقع (39)

  • UCSF Children's Hospital and Research Center at Oakland
    الرمز البريدي المؤكد
    أوكلاند، الولايات المتحدة· التوظيف
  • University of Minnesota Medical School
    الرمز البريدي المؤكد
    مينيابوليس، الولايات المتحدة· التوظيف
  • Mayo Clinic Childrens Center - PIN
    الرمز البريدي المؤكد
    روتشستر، الولايات المتحدة· التوظيف
  • Children's Medical Center Dallas
    الرمز البريدي المؤكد
    دالاس، الولايات المتحدة· التوظيف
  • Lysosomal Rare Disorders Research and Treatment Center
    الرمز البريدي المؤكد
    فيرفاكس، الولايات المتحدة· التوظيف
  • مستشفى أسترال الجامعي
    المدينة فقط
    Ciudad Autónoma Buenos Aires, Argentina· نشط غير مجند
  • Hospital de Niños de La Santisima Trinidad
    الرمز البريدي المؤكد
    قرطبة، الأرجنتين· التوظيف
  • مستشفى النساء والأطفال
    الرمز البريدي المؤكد
    شمال أديليد، أستراليا· التوظيف
  • مستشفى رويال ملبورن
    الرمز البريدي المؤكد
    باركفيل، أستراليا· التوظيف
  • Royal Children's Hospital Melbourne - PIN
    الرمز البريدي المؤكد
    باركفيل، أستراليا· التوظيف
  • Instituto Fernandes Figueira
    الرمز البريدي المؤكد
    ريو دي جانيرو، البرازيل· التوظيف
  • Hospital de Clinicas de Porto Alegre (HCPA) - PPDS
    الرمز البريدي المؤكد
    بورتو أليغري، البرازيل· التوظيف

أسئلة شائعة

What is AZ-3102?

AZ-3102 is a new medicine being tested in this study to see if it can help people with Niemann-Pick Type C, GM1 Gangliosidosis, or GM2 Gangliosidosis.

كم ستستغرق مدة الدراسة؟

If you join, your active participation in the study will last for 18 months.

هل سأعرف إذا كنت أحصل على الدواء أم حبة وهمية؟

No, neither you, your family, nor your doctors will know whether you are receiving AZ-3102 or the placebo until the study is over.

Can I stop taking part in the study?

نعم، يمكنك اختيار الانسحاب من الدراسة في أي وقت ولأي سبب، دون أن يؤثر ذلك على رعايتك الطبية المعتادة.

Why is a placebo used in this study?

A placebo helps researchers determine if any changes or improvements are truly due to the new medicine, AZ-3102, rather than other factors.

كيفية معرفة المزيد

Patient Advocacy Representative

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

هل أنت مهتم بالمشاركة؟

سجل اهتمامك

شارك تفاصيلك وفريق البحث لـ "A Study to Evaluate the Safety and Efficacy of Oral Nizubagl… "سيتواصل معك إذا كنت مؤهلاً. تحدث دائمًا إلى طبيبك قبل الموافقة على المشاركة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.